SunCoke Energy (SXC) shares climbed roughly 15% over the trailing 30 days, rising from about $9.57 to $11.01 as of late October 2026. A stronger-than-expected third-quarter earnings report and an updated full-year guidance outlook served as the primary near-term catalysts.

Vogenx (VOGX) shares have declined roughly 13% over the past 30 days, retreating from about $22.73 to near $19.73 as post-IPO momentum cooled. The pullback follows an unusually sharp run-up: the stock climbed from its $13.00 IPO price to an intraday high of $38.41 before giving back gains.

Draganfly shares fell roughly 31% over the trailing 30 days, from a close near $5.35 to about $3.69, as the stock gave back a sharp late-summer rally. The decline followed a surge above $6 in late August and early September driven by a Canadian Armed Forces drone contract and new strategic investment.

WYFI is up roughly +10.4% during regular market hours, trading near $10.51 versus the prior session's close of $9.52. The gain is an oversold rebound after the stock slid about -50% over the past month to a 52-week low of $9.31, pressured by convertible-note dilution and hedging-related shorting.

MBRX shares declined roughly 30% over the trailing 30 days, sliding from an adjusted close near $12.03 to about $8.37. The dominant catalyst was a 1-for-20 reverse stock split, announced October 16 and effective October 20, which triggered a sharp double-digit selloff.

Boeing shares declined roughly 13.5% over the last 30 days, falling from about $198 to near $171. The pullback intensified after third-quarter 2026 results, when an adjusted loss of $0.34 per share missed the roughly $0.21 consensus estimate.

BA is down -9.05% to $171.26 during regular trading, after slipping roughly -2.5% in premarket following its Q3 earnings release. The primary catalyst was a wider-than-expected Q3 loss: core EPS of -$0.34 versus the -$0.21 consensus, with revenue of $24.19B.

VOGX is up +10.27% during regular market hours, trading near $19.12 after closing the prior session at $17.34. The move is driven by broad strength in small-cap biotech as healthcare stocks rally, supported by sector M&A activity and positive clinical data elsewhere in the space.

CLS surged +11.95% to about $276 during Tuesday's regular session, rebounding from Monday's $246.65 close. Primary catalyst: a Q3 earnings beat, with revenue up +83% YoY to $5.83B and adjusted EPS of $3.30, both above consensus.

CTOS is up +13.54% in regular trading, near $10.23 versus a $9.01 prior close. The catalyst: Q3 results reported after Monday's close beat on EPS ($0.01 vs $0.0083 consensus) and raised FY2026 adjusted EBITDA guidance for the third time, plus SER revenue guidance.

VOYG is trading up +11.34% during regular market hours, climbing from a prior close of $24.78 to roughly $27.59. Primary catalyst is bullish momentum from its Interstellar Lab ISS mission-management contract (BioPod EDEN) plus the Griffin-1 lunar lander completing acceptance testing.

EQPT is trading up +11.13% intraday (~$18.07) versus its prior close of $16.26 during today's regular session. The advance extends follow-through from the Oct. 19 raised FY2026 outlook, lifting rental-segment revenue growth guidance to 43% from 33% and total revenue to $5.81B–$6.05B.

YD Bio (YDES) is up +10.59% in regular trading, climbing from a $5.29 close to about $5.85 intraday. The gain extends an end-of-month rebound fueled by AI health integrations: a JoiiUp partnership adding its cancer-risk assessment to a corporate wellness app, plus an EG BioMed 10-cancer AI assessment launch.

MFIC surged +23.56% during the regular session, climbing from $8.36 to roughly $10.33, its largest single-day move in recent history. The catalyst was Ares Capital's agreement to acquire MFIC from Apollo Global Management in a ~$2.6 billion enterprise-value, cash-and-stock transaction.

MBRX is up +19.89% intraday to about $8.50 from a prior close of $7.09, with the move occurring during regular market hours. The advance extends momentum around its lead candidate Annamycin and the pivotal MIRACLE Phase 2/3 AML trial, following positive preliminary unblinded efficacy data versus control.

KNSA shares are up +19.43% to $87.16 during regular trading, extending a strong premarket surge after reporting results. Primary catalyst: Q3 earnings beat — EPS of $0.56 versus $0.37 consensus, with revenue up +58% YoY to $286M versus $260.7M expected.

HRI gained +15.2% to about $146.45 in regular trading, gapping higher premarket from a prior close of $127.13. Primary catalyst: Q3 2026 earnings beat — adjusted EPS of $3.91 versus ~$2.92 consensus, on record revenue of $1.36 billion (+4.6% YoY).

SOFI is up roughly +13.90% to about $16.47, surging after gapping higher premarket and holding its gains into the regular session. Primary catalyst: Q3 2026 results beat expectations, with adjusted EPS of $0.18 and revenue up ~44% to a record ~$1.39 billion, driven by a 71% jump in loan originations.

FXHO is trading up +13.02% to $7.03 during regular market hours, rebounding from the prior session's $6.22 close. The gain follows a roughly -35% slide over the past month that left shares deeply oversold, pointing to short-covering and a technical bounce.

Korro Bio (KRRO) shares climbed roughly +40% over the trailing 30 days, rebounding from about $9.57 to above $13.40. The rally was driven primarily by positive preclinical data for KRRO-111, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD), announced on October 22, 2026.